MORE►
David D. Halbert
David Halbert, founder, chairman, and CEO of Caris Life Sciences. [Courtesy: Caris]
North Texas’ Caris Life Sciences Eyes $5.3B Valuation in Its Nasdaq IPO
by David Seeley | Jun 10, 2025
The Irving-based leader in precision oncology—which has raised $1.86 billion since 2018—plans to raise as much as $423.5 million when it goes public on the Nasdaq Global Select Market under the ticker symbol CAI.
by Lance Murray |
May 28, 2025
With $1.86 billion raised since 2018 and recent product launches, the North Texas life science company founded in 2008 is preparing for a public debut on the Nasdaq Global Select Market, following a $168 million growth capital round in April.
MORE►
by Lance Murray |
Jan 23, 2023
Caris Life Sciences, the Irving-based biotech company, announced Thursday that it closed a senior secured term loan providing up to $400 million in capital from OrbiMed and Braidwell, bringing its funding total since 2018 to roughly $1.7 billion....
MORE►
by Alex Edwards |
Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
MORE►
